# OnCo record paper-cho-mariposa-amivantamab-lazertinib-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cho-mariposa-amivantamab-lazertinib-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cho-mariposa-amivantamab-lazertinib-nejm-2024" ;
  schema:name "Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC"@en ;
  schema:description "MARIPOSA beat osimertinib, the standard first treatment, by about seven months before the cancer grew again. It is the first trial to do so, and the first to show that hitting EGFR two ways at once is better than one."@en ;
  schema:url <https://onco.cc/key-papers/paper-cho-mariposa-amivantamab-lazertinib-nejm-2024/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2403614>, <https://pubmed.ncbi.nlm.nih.gov/38924756/>, <https://clinicaltrials.gov/study/NCT04487080> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2403614> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Cho BC, Lu S, Felip E, et al." ;
  onco:related <https://onco.cc/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/>, <https://onco.cc/key-papers/paper-flaura-nejm-2018/>, <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/mariposa/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/nejm/> .